ArticleCritical care medicine2014
Leukocyte infiltration and activation of the NLRP3 inflammasome in white adipose tissue following thermal injury.
Article in Critical care medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis.Journal of Alzheimer's disease : JAD · 2018 · on this mapPooled it
- Cytosolic nucleic acid sensing as driver of critical illness: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2025Review
- NLRP3: a key regulator of skin wound healing and macrophage-fibroblast interactions in mice.Cell communication and signaling : CCS · 2025Article
- The NLRP3 inflammasome in burns: a novel potential therapeutic target.Burns & trauma · 2024Review
- An Overview of Recent Developments in the Management of Burn Injuries.International journal of molecular sciences · 2023Review
- Review
- Multifactorial pathways in burn injury-induced chronic pain: novel targets and their pharmacological modulation.Molecular biology reports · 2022Review
- Adipose tissue: a neglected organ in the response to severe trauma?Cellular and molecular life sciences : CMLS · 2022Review
- NLRP3 knockout enhances immune infiltration and inflammatory responses and improves survival in a burn sepsis model.Immunology · 2022Article
- Innate Immune System Response to Burn Damage-Focus on Cytokine Alteration.International journal of molecular sciences · 2022Review
- [New understanding on the immunity for severe infections and complications in burns and trauma].Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns · 2021Article
- Immunological approaches and therapy in burns (Review).Experimental and therapeutic medicine · 2020Review
- NLRP3 Inflammasome in Inflammation and Metabolism: Identifying Novel Roles in Postburn Adipose Dysfunction.Endocrinology · 2020Review
- NLRP3 inflammasome activity is required for wound healing after burns.Translational research : the journal of laboratory and clinical medicine · 2020Article
- Adipose Tissue Metabolic Function and Dysfunction: Impact of Burn Injury.Frontiers in cell and developmental biology · 2020Review
- NLRP3 inflammasome mediates white adipose tissue browning after burn.American journal of physiology. Endocrinology and metabolism · 2019Article
- Aggregated and Hyperstable Damage-Associated Molecular Patterns Are Released During ER Stress to Modulate Immune Function.Frontiers in cell and developmental biology · 2019Article
- NLRP3 Inflammasome Modulates Post-Burn Lipolysis and Hepatic Fat Infiltration via Fatty Acid Synthase.Scientific reports · 2018Article
- Accumulation of myeloid lineage cells is mapping out liver fibrosis post injury: a targetable lesion using Ketanserin.Experimental & molecular medicine · 2018Article
- Pathophysiological Response to Burn Injury in Adults.Annals of surgery · 2018Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
objectivesSevere thermal injury is associated with extreme and prolonged inflammatory and hypermetabolic responses, resulting in significant catabolism that delays recovery or even leads to multiple organ failure and death. Burned patients exhibit many symptoms of stress-induced diabetes, including hyperglycemia, hyperinsulinemia, and hyperlipidemia. Recently, the nucleotide-binding domain, leucine-rich family (NLR), pyrin-containing 3 (NLRP3) inflammasome has received much attention as the sensor of endogenous "danger signals" and mediator of "sterile inflammation" in type II diabetes. Therefore, we investigated whether the NLRP3 inflammasome is activated in the adipose tissue of burned patients, as we hypothesize that, similar to the scenario observed in chronic diabetes, the cytokines produced by the inflammasome mediate insulin resistance and metabolic dysfunction.
designProspective cohort study.
settingRoss Tilley Burn Centre & Sunnybrook Research Institute. PATIENTS: We enrolled 76 patients with burn sizes ranging from 1% to 70% total body surface area. All severely burned patients exhibited burn-induced insulin resistance and hyperglycemia.
interventionsNone. MEASUREMENTS AND MAIN
resultsWe examined the adipose tissue of control and burned patients and found, via flow cytometry and gene expression studies, increased infiltration of leukocytes-especially macrophages-and evidence of inflammasome priming and activation. Furthermore, we observed increased levels of interleukin-1β in the plasma of burned patients when compared to controls.
conclusionsIn summary, our study is the first to show activation of the inflammasome in burned humans, and our results provide impetus for further investigation of the role of the inflammasome in burn-induced hypermetabolism and, potentially, developing novel therapies targeting this protein complex for the treatment of stress-induced diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.